Yeda Research and Develpment & Co. Ltd

Immunobrain Checkpoint, Inc.

Neuroquest Inc.

Michal Eisenbach-Schwartz

Kuti Baruch

Neta Rosenzweig

Ester Yoles

Jonathan Kipnis

David L Hirschberg

Irun R Cohen

Ehud Hauben

Oleg Butovsky

Orly Spiegler

Michael Sela

Jan Egebjerg

Michal Cardon-Yaakov

Carol David

Valentin Fulga

Berit Olsen Krogh

Pierre Beserman

Allan Jensen

Eti Yoles

Matityahu Fridkin

Ruth Arnon

Rina Aharoni

Alon Monsonego

Shoshana Eitan

Esther Yoles

Inbal Benhar Bar-On

Ravid Shechter

Omer Miller

Sharon Bakalash

Gil M Lewitus

Noga Ron-Harel

Ronit Kleiner Bakimer

Issar Ash

Gila Moalem

Noga Ron

Yaniv Ziv

Raya Eilam

A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.

Reducing systemic regulatory T cell levels or activity for treatment of amyotrophic lateral sclerosis

A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

The present specification discloses modified anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. The present specification also discloses nucleic acid sequences and expression constructs encoding such modified anti-PD-L1 antibodies as well as methods of making such modified anti-PD-L1 antibodies. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.

Modified anti-PD-L1 antibody and methods and uses for treating a neurodegenerative disease

The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.

Reducing systemic regulatory T cell levels or activity for treatment of a retinal degeneration disorder

Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the CNS

Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS

A monocyte subpopulation having a low relative amount, or substantially devoid, of CD3cells, CD19cells, CD56cells and optionally CD16cells is provided, wherein the monocyte subpopulation is for use in inhibition of neuronal degeneration, protection of neurons from glutamate toxicity or promotion of nerve regeneration in the retina or optic nerve, wherein the retina or optic nerve is damaged by a disease, disorder or condition of the eye, or for treatment of an inflammatory disease, disorder or condition of the eye.

Human monocyte sub-population for treatment of eye diseases and disorders

Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease

Growing community of inventors

Rehovot, Israel

Michal Eisenbach-Schwartz